Thrombocytopenia And Thrombocytopenic PurpuraThrombocytopenia And Thrombocytopenic Purpura Elisabeth Sosa, MSN, ARNP, AOCNP Elisabeth Sosa, MSN, ARNP, AOCNP is a certified adult oncology

nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1

Thrombocytopenia And

Thrombocytopenic Purpura

Elisabeth Sosa, MSN, ARNP, AOCNP

Elisabeth Sosa, MSN, ARNP, AOCNP is a certified adult oncology nurse practitioner. She

practices within a large private-practice hematology/medical oncology group in Central

Florida. She has previously been published in the Clinical Journal of Oncology Nursing

(CJON).

ABSTRACT

Thrombocytopenia can occur for a number of different reasons. These

include congenital disorders, bone marrow disorders, infectious causes, drug

effect, and immunologic causes. The purpose of this course is to provide a

brief review of thrombocytopenia, with a focus on idiopathic

thrombocytopenic purpura (ITP). The course will discuss the definition of

thrombocytopenia, as well as grading the severity. This course will also

review complications of thrombocytopenia, including bleeding. Readers are

provided with an understanding of how thrombocytopenia and ITP are

treated and knowledge of bleeding precautions. Bleeding precautions

increase patient safety when the platelet count is dangerously low. It is

important that health care personnel have an understanding of

thrombocytopenia so that patients can be treated appropriately and

complications can be avoided.

KEYWORDS: thrombocytopenia, platelets, hematology, idiopathic

thrombocytopenic purpura


Continuing Nursing Education Course Planners

William A. Cook, PhD, Director, Douglas Lawrence, MA, Webmaster,

Susan DePasquale, MSN, FPMHNP-BC, Lead Nurse Planner

Policy Statement

This activity has been planned and implemented in accordance with the

policies of NurseCe4Less.com and the continuing nursing education

requirements of the American Nurses Credentialing Center's Commission on

Accreditation for registered nurses. It is the policy of NurseCe4Less.com to

ensure objectivity, transparency, and best practice in clinical education for

all continuing nursing education (CNE) activities.

Continuing Education Credit Designation

This educational activity is credited for 2 hours. Nurses may only claim credit

commensurate with the credit awarded for completion of this course activity.

Pharmacology content is 0.5 hours (30 minutes).

Statement of Learning Need

Nurses are required to be knowledgeable about how thrombocytopenia

occurs. ITP, idiopathic thrombocytopenia, is a cause of thrombocytopenia that

nurses need to understand and be able to educate patients about in terms of

bleeding risk and disease management.


Course Purpose

To help nurses develop an understanding of the treatment of

thrombocytopenia, specifically idiopathic thrombocytopenic purpura (ITP), as

well as the bleeding precautions in patients with thrombocytopenia.

Target Audience

Advanced Practice Registered Nurses and Registered Nurses

(Interdisciplinary Health Team Members, including Vocational Nurses and

Medical Assistants may obtain a Certificate of Completion)

Course Author & Planning Team Conflict of Interest Disclosures

Elisabeth Sosa, MSN, ARNP, AOCNP, William S. Cook, PhD,

Douglas Lawrence, MA, Susan DePasquale, MSN, FPMHNP-BC –

all have no disclosures.

Acknowledgement of Commercial Support

There is no commercial support for this course.

Activity Review Information

Reviewed by Susan DePasquale, MSN, FPMHNP-BC.

Release Date: 1/1/2016 Termination Date: 7/14/2017

Please take time to complete a self-assessment of knowledge, on page 4, sample questions before reading the article.

Opportunity to complete a self-assessment of knowledge learned will be provided at the end of the course.


1. Your patient has a platelet count of 7,000. What grade is the

thrombocytopenia?

a) Grade I

b) Grade II

c) Grade III

d) Grade IV

2. Which of the following medications is NOT known to cause

thrombocytopenia?

a) Heparin

b) Lisinopril

c) Penicillin

d) Valproic acid

3. How is ITP diagnosed?

a) Using a special blood test that is sent to a reference lab

b) Bone marrow biopsy

c) It is a diagnosis of exclusion

d) Ultrasound of the abdomen

4. Which of the following is a complication of thrombocytopenia?

a) Intracranial bleeding

b) Anemia

c) GI bleed

d) All of the above

5. Which of the following is NOT known to cause thrombocytopenia?

a) Bone marrow disorder

b) Vitamin D deficiency

c) HIV

d) Rheumatoid arthritis


Introduction

The following case study may be seen in the outpatient primary care setting.

The objective of this case study is to illustrate how some patients with

thrombocytopenia, specifically idiopathic thrombocytopenic purpura (ITP),

may present. Suggestions will be made later in this course on how the

patient should be treated, including appropriate diagnostic testing,

pharmacological treatment, and supportive care.

Case Study: Mary

Mary is a 45-year-old female with no significant medical history. She

develops symptoms including urinary frequency and pain when urinating.

She presents to her primary care physician (PCP) and is diagnosed with a

urinary tract infection. After verifying her allergies, the physician

prescribes a course of Bactrim for the patient. After several days, Mary’s

urinary symptoms resolve. However, she begins to notice bruising on her

arms and legs. She has not experienced any trauma to these areas. Mary

also has several nosebleeds.

Mary returns to her PCP to discuss her new symptoms. A complete blood

count (CBC) is drawn and notes a normal white blood cell count (WBC) of

5.4 and normal hemoglobin of 13.1. However, the platelet count is

abnormal at 45,000. Mary’s medical records do not show evidence of

thrombocytopenia in the past. Mary’s PCP refers her to a hematologist

right away for further evaluation of thrombocytopenia.


Definition of Thrombocytopenia

Platelets are a type of blood cell that are produced in the bone marrow by

megakaryocytes. The megakaryocytes inside the bone marrow release

platelets, or fragments of cytoplasm, into the bloodstream. Once in the

bloodstream, the platelets exist for eight to twelve days. Typically,

phagocytes in the spleen remove platelets from the circulation.

Approximately one third of platelets are stored in the spleen (Baldwin,

2003).

Normal platelet count is between 150 and 400. Thrombocytopenia is defined

as a platelet count less than 150 (Lichtman, Kaushansky, Kipps, Prchal, &

Levi, 2011; Winkeljohn, 2013). However, there are varying degrees of

thrombocytopenia. Grading is illustrated in Table 1. Platelets play an

important role in hemostasis, which is the process of a blood clot being

formed from the fluid part of blood. When there is injury to the vessel wall,

platelets create a hemostatic plug to stop the bleeding. If there is a problem

with platelet production or function, or if platelet destruction is occurring,

thrombocytopenia can ensue and lead to significant bleeding complications

(Rodriguez & Gobel, 2011).

Table 1. National Cancer Institute Common Terminology Criteria for Adverse

Events: Thrombocytopenia

Grade 1 2 3 4 5

<LLN-

75,000/mm^3

<75,000-

50,000/mm^3

<50,000-

25,000/mm^3

<25,000/mm^3 -

LLN- lower limit of normal. (National Cancer Institute, 2009)


Causes of Thrombocytopenia

There are many reasons why a low platelet count may be noted on lab work.

While the focus of this course is ITP, it is important to have an

understanding of other causes of thrombocytopenia, as ITP is a diagnosis of

exclusion. For example, psuedothrombocytopenia may occur. This happens

when platelets clump together and give a falsely low platelet count. The

platelets can clump when they are placed in lavender EDTA

(ethylenediaminetetraacetic acid) tubes. It is important to recollect the sample

in a blue sodium citrate tube to determine if the patient does in fact have

thrombocytopenia. Dilutional thrombocytopenia can occur when a patient

receives a large number of red blood cell transfusions.

Normally, the patient would need to have received more than 15 to 20

transfusions in a 24-hr period for this phenomenon to occur. Distributional

thrombocytopenia occurs when a large percentage of platelets are stored in

the spleen instead of in circulation. This is seen in patients with

splenomegaly, cirrhosis, and portal hypertension. While the actual number of

platelets is normal, the peripheral count is low and this will be noted as

thrombocytopenia on the CBC. Bleeding is uncommon in this case (Baldwin,

2003; Lichtman et al., 2011).

Major Causes Of Thrombocytopenia

The major causes of thrombocytopenia are noted below and will be

discussed in more detail in the following paragraphs.

Reduced platelet production

Increased platelet destruction


As mentioned previously, platelets are produced in the bone marrow. If

cancer penetrates the bone marrow, such as in leukemia, lymphoma,

metastatic cancer with bone involvement, or multiple myeloma, platelet

production suffers. In oncology patients being treated with radiation therapy

in which the radiation field involves large amounts of bone marrow, platelet

production also diminishes. Certain drugs can also affect platelet production

(see below).

Certain viral infections, such as rubella, mumps, Epstein-Barr,

cytomegalovirus, HIV, and varicella, can also inhibit platelet production. This

can also happen in patients with typhus and Rocky Mountain spotted fever.

Chronic alcohol abuse and illicit drug use also affect platelet production. In

addition, patients with vitamin B12, folate, and/or iron deficiency may also

have thrombocytopenia. These substances are necessary for normal bone

marrow function (Baldwin, 2003; Lichtman et al., 2011).

Increased destruction of platelets can happen for many different reasons,

but can be categorized into immunologic and nonimmunologic reasons.

Immunologic destruction occurs due to antibodies. Sometimes this happens

because of autoantibodies. This is noted in chronic lymphocytic leukemia,

systemic lupus erythematosus, rheumatoid arthritis, thyroiditis,

inflammatory bowel disease, and autoimmune hemolytic anemia. On the

other hand, thrombocytopenia can take place due to alloantibody-mediated

destruction. This is seen after transfusions and bone marrow/stem cell

transplantation. This is also seen in pregnancy, such as with preeclampsia,

eclampsia, gestational thrombocytopenia, and HELLP syndrome (hemolysis,

elevated liver tests and low platelet count). Immunologic platelet destruction


is also noted in septic patients. A number of drugs can also lead to platelet

destruction (Baldwin, 2003; Lichtman et al., 2011).

Nonimmunologic causes of platelet destruction also contribute to

thrombocytopenia. This is seen in disseminated intravascular coagulation

(DIC), thrombotic thrombocytopenic purprura (TTP), hemolytic uremic

syndrome, and sepsis. In patients on cardiopulmonary bypass, the machine

may physically damage platelets (Baldwin, 2003).

Drugs That May Cause Thrombocytopenia

Medications that may cause thrombocytopenia are listed below (Baldwin,

2003 and Lichtman et al., 2011):

Drugs affecting platelet production:

Chemotherapy

Estrogen

Anticonvulsants

Thiazide diuretics

Drugs causing platelet destruction:

Heparin (Heparin-Induced Thrombocytopenia HIT)

Barbiturates

Gold salts

H2 blockers

Methyldopa


Digoxin

Procainamide

Penicillin

Sulfonamides

Quinidine

Quinine

Valproic acid

ITP: What is it?

The list of causes of thrombocytopenia is quite long and exhaustive. ITP is

an acquired condition with no obvious cause of thrombocytopenia and is

therefore diagnosed by excluding other causes of thrombocytopenia. In

adults, ITP usually does not resolve by itself. In patients with ITP, platelets

have a shorter survival time in the bloodstream due to being stored in the

spleen and being destroyed by antibodies. These antibodies may also impair

platelet production. The incidence of ITP is higher in young women than

young men. In older adults, the incidence is equal (Lichtman et al., 2011).

ITP: How is it diagnosed?

In order to diagnose ITP, other causes of thrombocytopenia must be

excluded. This entails a thorough review of medications, as well as a

complete history and physical. Use of herbal products should be discussed.

Specifically, patients should be asked about use of chamomile, ginger,

gingko, and kelp. In addition to asking about alcohol use, usage should be

quantified. Patients should be asked about past surgeries and any bleeding

complications (Baldwin, 2003, Winkeljohn, 2013 and Winkeljohn, 2010).


Physical examination should focus on ecchymosis, petechiae, and spleen and

liver size. As far as diagnostic tests are concerned, a CBC with manual

differential should be ordered. Viral studies, such as human

immunodeficiency virus (HIV) and hepatitis, should also be done to rule out

infectious causes of thrombocytopenia. The patient should be assessed for

nutritional deficiencies, which include vitamin B12 level, folic acid level, and

iron studies. Coagulation studies should be ordered as well. The presence of

bleeding should be assessed through urinalysis and stool testing for occult

blood. In addition, liver enzymes should be checked. An abdominal

ultrasound is useful in determining the presence of an enlarged spleen. Bone

marrow biopsy is not routinely done, unless the patient is older than 60

years of age (Baldwin, 2003, Winkeljohn, 2013, and Winkeljohn, 2010).

Complications of Thrombocytopenia

Patients usually do not experience symptoms until the platelet count falls

below 20,000. The major complication of thrombocytopenia is bleeding. This

includes spontaneous bleeding from the mouth, nose, and GI tract. Patients

may also have hematuria and hemoptysis. Women may experience

menorrhagia. Two very serious complications, which typically do not occur

unless the platelet count is less than 5,000, are spontaneous intracranial

bleeding and uncontrollable gastrointestinal bleeding. In patients undergoing

surgical procedures, they may experience extended bleeding. Blood loss can

lead to anemia, and may be significant enough to require transfusions of

packed red blood cells (Baldwin, 2003).

Patient Education: Bleeding Precautions

It is very important that nurses educate thrombocytopenic patients about

their risk of bleeding and interventions to minimize the risk. Patients should


avoid activities that increase the risk of bleeding. For example,

thrombocytopenic patients should use soft toothbrushes and be careful when

flossing to decrease the risk of oral bleeding. Patients should be instructed to

shave with electric razors instead of blades. Also, they should be advised not

to engage in contact sports. Patients should also be assessed for risk of falls.

Nurses should discuss tips to prevent falls, such as creating a safe

environment in the home. Patients, especially elderly patients, may need

assistive devices (Winkeljohn, 2013).

Patients with low platelet counts should avoid unnecessary invasive

procedures. These patients should also be instructed on a bowel regimen to

prevent constipation and straining. Thrombocytopenic patients should not

use suppositories or enemas. Other activity to avoid includes sexual activity,

which can increase risk of bleeding. Patients should be advised to use

lubricant when engaging in sexual activity. If the platelet count is severely

decreased, they should abstain. Patients should also be instructed to avoid

certain medications that may affect platelet function, such as ibuprofen and

aspirin (Winkeljohn, 2013).

Bleeding Precautions

Education of patients with thrombocytopenia are highlighted below:

Use soft toothbrush and be careful when flossing

Avoid shaving; if you must shave, use an electric razor

No enemas or suppositories

Use lubrication when engaging in sexual activity

No contact sports

Prevent falls


Avoid invasive procedures if at all possible

General Treatment of Thrombocytopenia

Treatment of thrombocytopenia varies and is based on cause. For example,

in patients with HIT (heparin-induced thrombocytopenia), all heparin should

be discontinued immediately. Lovenox is also not recommended (Sanofi-

Aventis, 2013). Other forms of anticoagulation should be used instead.

Platelet transfusions are generally not indicated due to risk of clots. In drug-

induced thrombocytopenia, the substance causing thrombocytopenia should

be stopped right away. If the patient is asymptomatic, no further

intervention is required and the platelet count should return to normal in

seven to ten days. Platelet transfusion is only indicated if there is a high risk

of bleeding or the platelet count is less than 5,000 (Baldwin, 2003).

In patients with chemotherapy-induced thrombocytopenia, platelet

transfusions are usually warranted if the platelet count is less than 10,000.

If bleeding is present, such as epistaxis or rectal bleeding, platelet

transfusions should be arranged even if the platelet count is over 10,000. If

patients require an invasive procedure, such as endoscopy or bone marrow

biopsy, the platelet count should be at least 50,000 (Damron et al., 2009).

Treatment of ITP

Corticosteroids

Idiopathic thrombocytopenic purpura is initially treated with corticosteroids,

usually prednisone at a dose of 1mg/kg daily. Once platelets increase,


prednisone should be tapered. The tapering schedule is based on the platelet

count. The average response time is seven to 28 days. Dexamethasone is

sometimes used as well. The dose is usually 40 mg daily for four days and

may be repeated. Oftentimes, patients with ITP will respond to initial

treatment, but may relapse. If this happens, corticosteroids can be used

again.

Side effects of corticosteroids include increased appetite, weight gain,

difficulty sleeping, and headaches. Prolonged use of steroids can cause

osteoporosis, immunosuppression, and diabetes mellitus (Lichtman et al.,

2011, Winkeljohn, 2010, and Winkeljohn, 2013).

Immunoglobulin (IVIG)

Intravenous immunoglobulin (IVIG) is another treatment option. Platelets

will generally increase quite rapidly, with a response rate of two to seven

days. IVIG is generally infused slowly at first, then titrated as the patient

tolerates. Patients usually receive premedication with acetaminophen and

diphenhydramine to prevent infusion reactions. The large volume of the

infusion can also be a concern.

Side effects include headaches, chest pain/tightness, shortness of breath,

fevers, chills, back pain, and flu-like symptoms. More serious complications

include renal failure, meningitis, anaphylaxis, and thromboembolic events

(Shelton, Griffin, & Goldman, 2006, and Winkeljohn, 2013).


Anti-Rh (D) immune globulin

Anti-Rh(D) immune globulin is another treatment option that is given

intravenously. The response time is about three to seven days and response

usually lasts for greater than three weeks. This treatment is not indicated for

patients who are Rh negative or who have undergone a splenectomy.

Side effects of treatment include hemolysis, headaches, fever, chills, nausea,

vomiting, and allergic reactions (Lichtman et al., 2011, and Winkeljohn,

2013).

Rituximab

Rituximab can be used if the other options listed above were not effective.

This medication is an infusion given weekly for four weeks. Response is

usually seen in about a week. This medication can be quite costly. Side

effects include infusion reactions, including anaphylactic-type reactions.

Fevers, chills, rigors, and headaches may also occur (Winkeljohn, 2013).

Splenectomy

Another option, if previous treatments are deemed ineffective, is removal of

the spleen (splenectomy). However, this treatment is usually not done until

at least six months after diagnosis. Increase in platelets is usually noted

several days after splenectomy.


Complications include infection, abscess, adhesions, and hernia. Patients

should receive the haemophilus influenzae type B, meningococcal, and

pneumococcal vaccines at least two weeks before splenectomy.

Patients without a spleen are also at increased risk of infection for the rest of

their lives and should be properly educated (Lichtman et al., 2011, and

Winkeljohn, 2013).

Eltrombopag

Eltrombopag is a newer oral medication for ITP. This medication is taken

daily. If discontinued, the platelet count will decrease. Response is noted in

seven to 28 days. The medication is usually well tolerated.

Side effects include bone marrow fibrosis and changes in liver function tests.

Patients should be monitored for thrombotic and thromboembolic

complications (Winkeljohn, 2013).

Romiplostim

Another fairly new medication is romiplostim, which is given subcutaneously

once a week. Patients remain on this medication indefinitely. If discontinued,

the platelet count will decrease.

Response is seen in seven to ten days. Side effects are similar to those seen

in eltrombopag (Winkeljohn, 2013).


On Reflection: Mary (case study at the beginning of the course)

Mary’s platelet count is 45,000, which is consistent with Grade III

thrombocytopenia. She presents to the hematologist immediately for further

evaluation. The hematologist performs a thorough history, including review

of medications she is currently taking, as well as medications she has taken

recently. The hematologist is concerned about recent exposure to Bactrim

and advises Mary to avoid this medication in the future. The rest of her

history does not reveal any significant findings.

The hematologist performs a physical exam and notes scattered bruises. He

does not appreciate hepatosplenomegaly. The physician proceeds with

further workup to include complete blood count (CBC), peripheral smear,

complete metabolic panel including liver function tests, and abdominal

ultrasound. He also asks the phlebotomist to collect a CBC in a blue tube. He

also checks HIV, hepatitis, CMV, and EBV. In addition, he orders iron

studies, as well as B12 and folic acid levels.

The office nurse educates Mary on signs and symptoms to report

immediately. She also discusses bleeding precautions with the patient. Mary

has no evidence of bleeding and therefore does not require treatment at this

time. Mary is advised to return to the office in one week to discuss results

and repeat the CBC.

At Mary’s next visit, her workup is overall negative. Repeat CBC now shows

an improved platelet count of 100,000. It is determined that Mary likely

experienced drug-induced thrombocytopenia due to Bactrim. However, the

doctor brings Mary back for another CBC in two weeks. Platelets are now

back to normal and bruising has resolved.


Summary

Thrombocytopenia can occur for many different reasons. It is important that

the cause of thrombocytopenia is determined promptly so that patients can

be treated appropriately. Thrombocytopenia can lead to bleeding

complications, including severe and life-threatening gastrointestinal bleeding

and intracranial bleeding. Patients may require platelet transfusions. If blood

loss is severe, patients may even require transfusions of packed cells. ITP is

a diagnosis of exclusion when other causes of thrombocytopenia are ruled

out.

Nurses play an integral role in caring for these patients and keeping them

safe. Teaching patients and their families about bleeding precautions often

becomes the responsibility of the nurse. Following bleeding precautions and

preventing falls can help prevent further harm. As part of the health care

team, nurses are in an excellent place to improve patient outcomes.

Please take time to help NurseCe4Less.com course planners evaluate the nursing knowledge needs met by completing the self-assessment

of Knowledge Questions after reading the article, and providing

feedback in the online course evaluation.

Completing the study questions is optional and is NOT a course requirement.


1. Your patient has a platelet count of 7,000. What grade is the

thrombocytopenia?

a. Grade I

b. Grade II

c. Grade III

d. Grade IV

2. Which of the following medications is NOT known to cause

thrombocytopenia?

a. Heparin

b. Lisinopril

c. Penicillin

d. Valproic acid

3. Which patient would you LEAST expect to develop

a. 67-year-old female with acute leukemia receiving chemotherapy

b. 25 year old male with no past medical history, no history of

infections, and not taking any medications

c. 30 year old female who is 38-weeks pregnant and has proteinuria

d. 55-year-old female with history of chronic alcohol abuse and

cirrhosis

4. How is ITP diagnosed?

a. Using a special blood test that is sent to a reference lab

b. Bone marrow biopsy

c. It is a diagnosis of exclusion

d. Ultrasound of the abdomen


5. Which of the following is a complication of thrombocytopenia?

a. Intracranial bleeding

b. Anemia

c. GI bleed

d. All of the above

6. What should your female patient with a platelet count of 5,000

avoid?

a. Shaving her legs with a razor

b. Walking

c. Sexual activity

d. Both A & C are correct choices

7. Which of the following is NOT known to cause

thrombocytopenia?

a. Bone marrow disorder

b. Vitamin D deficiency

c. HIV

d. Rheumatoid arthritis

8. In patients with HIT (heparin-induced thrombocytopenia),

what should they avoid?

a. Heparin

b. Lovenox

c. Platelet transfusions

d. All of the above


9. You are caring for a patient with ITP. What would be the

standard starting dose of prednisone in a patient who weighs

65 kg?

a. 40 mg daily for four days

b. 30 mg twice a day

c. 65 mg daily

d. 65 mg twice a day

10. Your patient with ITP has O negative blood type. Which

treatment is NOT appropriate for this patient?

a. Anti-Rh(D) immune globulin

b. IVIG (intravenous immune globulin)

c. Dexamethasone

d. All of the above treatments are appropriate for the patient

Correct Answers:

1. D. Grade IV

2. B. Lisinopril

3. B. 25 year old male with no past medical history, no history of

infections, and not taking any medications

4. C. It is a diagnosis of exclusion

5. D. All of the above

6. D. Both A & C are correct choices

7. B. Vitamin D deficiency

8. D. All of the above

9. C. 65 mg daily

10. A. Anti-Rh(D) immune globulin


References Section

The reference section of in-text citations include published works intended as

helpful material for further reading. Unpublished works and personal

communications are not included in this section, although may appear within

the study text.

1. Baldwin, P. D. (2003). Thrombocytopenia. Clinical Journal of Oncology

Nursing, 7(3), 349- 352.

2. Damron, B. H., Brant, J. M., Belansky, H. B., Friend, P. J., Samsonow,

S., & Schaal, A. (2009). Putting evidence into practice: Prevention and

management of bleeding in patients with cancer. Clinical Journal of

Oncology Nursing, 13(5), 573-583.

3. Lichtman, M. A., Kaushansky, K., Kipps, T. J., Prchal, J. T., & Levi, M.

M. (2011). Thrombocytopenia. In J. Shanahan & H. Lebowitz (Eds),

Williams manual of hematology eighth edition (pp.554-574). New

York: McGraw Hill Medical.

4. National Cancer Institute. (2009). Common terminology criteria for

adverse events v4.0 (NIH Publication No. 09-7473). Retrieved from

http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-

14_QuickReference_8.5x11.pdf

5. Rodriguez, A. L. & Gobel, B. H. (2011). Bleeding. In C. Yarbro, D.

Wujcik, & B. Gobel (Eds.), Cancer Nursing (pp. 745-771). Sudbury,

Massachusetts: Jones and Bartlett Publishers.

6. Sanofi-Aventis (2013). Lovenox prescribing information. Retrieved

from http://products.sanofi.us/lovenox/lovenox.html

7. Shelton, B. K., Griffin, J. M., & Goldman, F. D. (2006). Immune

globulin IV therapy: Optimizing care of patients in the oncology

setting. Oncology Nursing Forum, 33(5), 911-921.


8. Winkeljohn, D. (2010). Idiopathic thrombocytic purpura. Clinical

Journal of Oncology Nursing, 14(4), 411-413.

9. Winkeljohn, D. (2013). Diagnosis, treatment, and management of

immune thrombocytopenia. Clinical Journal of Oncology Nursing,

17(6), 664-666.

The information presented in this course is intended solely for the use of healthcare

professionals taking this course, for credit, from NurseCe4Less.com. The information is

designed to assist healthcare professionals, including nurses, in addressing issues

associated with healthcare.

The information provided in this course is general in nature, and is not designed to address

any specific situation. This publication in no way absolves facilities of their responsibility for

the appropriate orientation of healthcare professionals. Hospitals or other organizations

using this publication as a part of their own orientation processes should review the

contents of this publication to ensure accuracy and compliance before using this publication.

Hospitals and facilities that use this publication agree to defend and indemnify, and shall

hold NurseCe4Less.com, including its parent(s), subsidiaries, affiliates, officers/directors,

and employees from liability resulting from the use of this publication.

The contents of this publication may not be reproduced without written permission from

NurseCe4Less.com.

Documents

Thrombocytopenia And Thrombocytopenic PurpuraThrombocytopenia And Thrombocytopenic Purpura Elisabeth Sosa, MSN, ARNP, AOCNP Elisabeth Sosa, MSN, ARNP, AOCNP is a certified adult oncology